Erratum.
In the News & Comment article "Court rejects Rifkin in biotech cases" by Mark Crawford (9 Jan., p. 159), the Food and Drug Administration (FDA) was incorrectly portrayed as having abandoned biotechnology guidelines issued by the Biotechnology Science Coordinating Committee. The agency continues to endorse the guidelines, but notes they "do not have specific regulatory significance for FDA."